Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10746554 | 0.95 | TP53 (0.67) | RAB9AGAATP53NPC1LMNA | |
| SCHEMBL7899214 | 0.95 | TP53 (0.67) | RAB9AGAATP53NPC1LMNA | |
| SCHEMBL7889286 | 0.95 | TP53 (0.67) | RAB9AGAATP53NPC1LMNA | |
| SCHEMBL15019645 | 0.95 | TP53 (0.67) | RAB9AGAATP53NPC1LMNA | |
| SCHEMBL7896219 | 0.92 | GAA (0.54) | RAB9AGAATP53NPC1LMNA | |
| Benzene SCHEMBL28017867 | 0.89 | MEN1 (0.52) | RAB9AGAATP53NPC1LMNA | |
| SCHEMBL3083855 | 0.85 | PRSS1 (0.53) | RAB9AGAAPRSS1TMPRSS2 | |
| SCHEMBL5309757 | 0.84 | PARP10 (0.66) | RAB9ANPC1MAPTTSHRSMN1; SMN2 | |
| SCHEMBL27108630 | 0.83 | PRSS1 (0.53) | MAPTSMN1; SMN2PRSS1TMPRSS2 | |
| SCHEMBL7897051 | 0.81 | PRSS1 (0.57) | TSHRPRSS1PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| US-6277998-B1 | REACTING 2-CYANO-4-OXO-4H-BENZOPYRAN COMPOUND WITH HYDROGEN SULFIDE AND THEN REACTING PROUDCT WITH ALKYL HALIDE; REACTING THE PRODUCT WITH HYDRAZINE OR ITS SALT AND THEN WITH NITROUS ACID COMPOUND TO OBTAIN TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-21 | — | — | US | disclosed |
| US-6191289-B1 | REACTING A 4-OXO-4H-BENZOPYRAN GROUP SUBSTITUTED WITH AMIDE OR A PHENYL GROUP IN ITS 2 POSITION IS REACTED WITH ANHYDROUS HYDRAZINE OR SALT IN PRESENCE OF CATALYST FOLLOWED BY REACTING WITH NITROUS ACID OR SALT TO FORM TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-02-20 | — | — | US | disclosed |
| US-5874593-A | SULFUR CONTAINING AMIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0711762-A1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | RAB9A 3681/4885GAA 3653/4885TP53 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.